<http://schema.org/description>
"Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2013-12-drug-combination-disease-subgroup-women.html>